Regulatory Effects of Cytokines on Spontaneous Pyroptosis in Neutrophils

Tong CHEN, Qian REN, Fengxia MA

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (4) : 497-508.

PDF(11270 KB)
Home Journals Acta Academiae Medicinae Sinicae
Acta Academiae Medicinae Sinicae

Abbreviation (ISO4): Acta Academiae Medicinae Sinicae      Editor in chief: Xuetao CAO

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(11270 KB)
Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (4) : 497-508. DOI: 10.3881/j.issn.1000-503X.16358
Original Articles

Regulatory Effects of Cytokines on Spontaneous Pyroptosis in Neutrophils

Author information +
History +

Abstract

Objective To explore the regulatory effects of cytokines interleukin(IL)-1β,IL-6,tumor necrosis factor alpha(TNF-ɑ),gamma interferon(IFN-γ),granulocyte colony-stimulating factor(G-CSF),and granulocyte-macrophage colony-stimulating factor(GM-CSF)on spontaneous pyroptosis in neutrophils.Methods Neutrophils isolated from mouse bone marrow by density-gradient centrifugation were cultured in vitro for 20 h with or without 10,50 or 100 ng/mL IL-1β,IL-6,IFN-γ,G-CSF or GM-CSF,or for 12 h with or without 1,10 or 50 ng/mL TNF-α.After incubation,cells were stained with annexin Ⅴ(AV)/propidium iodide(PI),and the proportions and absolute number of neutrophils undergoing different forms of cell death were determined by fluorescence microscopy combined with manual counting.Pyroptotic neutrophils were identified by cell morphology in conjunction with AV/PI staining.Flow cytometry with counting beads was employed to measure the proportions and number of AV/PI-stained Ly6g+neutrophils in different forms of cell death.Western blotting was employed to assess the cleavage and activation levels of cysteinyl aspartate-specific proteinase-3(caspase-3)and gasdermin E(GSDME).Results Treatment with IL-1β or IL-6 had no significant effect on the proportion or number of neutrophils undergoing spontaneous pyroptosis.After 12 h of treatment with TNF-α at 1,10,and 50 ng/mL,the proportions of pyroptotic neutrophils were(14.79±0.45)%,(19.99±3.02)%,and(20.66±1.99)%,respectively,higher than that[(10.22±1.12)%]in the untreated control(P=0.024,P<0.001,and P<0.001,respectively).Treatment with 10,50,and 100 ng/mL IFN-γ for 20 h reduced the proportion of pyroptotic neutrophils from(17.43±1.88)%to 12.00%(all P<0.001).G-CSF at 10,50,and 100 ng/mL reduced the proportion of pyroptotic cells to around 6.00%and greatly inhibited the cleavage of both caspase-3 and GSDME.After 20 h of treatment with 10,50,and 100 ng/mL GM-CSF,the proportions of pyroptotic neutrophils decreased to(7.52±0.53)%,(5.27±2.30)%,and(0.64±1.11)%,respectively.Conclusions Neither IL-1β nor IL-6 affects GSDME-mediated spontaneous pyroptosis in neutrophils.TNF-ɑ induces spontaneous pyroptosis in neutrophils,whereas IFN-γ,G-CSF,and GM-CSF demonstrate inhibitory effects.

Key words

cytokines / neutrophils / pyroptosis

Cite this article

Download Citations
Tong CHEN , Qian REN , Fengxia MA. Regulatory Effects of Cytokines on Spontaneous Pyroptosis in Neutrophils[J]. Acta Academiae Medicinae Sinicae. 2025, 47(4): 497-508 https://doi.org/10.3881/j.issn.1000-503X.16358

References

[1]
Qu J, Jin J, Zhang M, et al. Neutrophil diversity and plasticity:implications for organ transplantation[J]. Cell Mol Immunol, 2023, 20(9):993-1001.DOI:10.1038/s41423-023-01058-1.
[2]
Ley K, Hoffman HM, Kubes P, et al. Neutrophils:new insights and open questions[J]. Sci Immunol, 2018, 3(30):eaat4579.DOI:10.1126/sciimmunol.aat4579.
[3]
Hidalgo A, Chilvers ER, Summers C, et al. The neutrophil life cycle[J]. Trends Immunol, 2019, 40(7):584-597.DOI:10.1016/j.it.2019.04.013.
[4]
Luo HR, Loison F. Constitutive neutrophil apoptosis:mechanisms and regulation[J]. Am J Hematol, 2008, 83(4):288-295.DOI:10.1002/ajh.21078.
[5]
Ma F, Ghimire L, Ren Q, et al. Gasdermin E dictates inflammatory responses by controlling the mode of neutrophil death[J]. Nat Commun, 2024, 15(1):386.DOI:10.1038/s41467-023-44669-y.
[6]
Cohen SB, Moreland LW, Cush JJ, et al. A multicentre,double blind,randomised,placebo controlled trial of anakinra(Kineret),a recombinant interleukin 1 receptor antagonist,in patients with rheumatoid arthritis treated with background methotrexate[J]. Ann Rheum Dis, 2004, 63(9):1062-1068.DOI:10.1136/ard.2003.016014.
[7]
Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder(TANGO):an open-label,multicentre,randomised,phase 2 trial[J]. Lancet Neurol, 2020, 19(5):391-401.DOI:10.1016/S1474-4422(20)30070-3.
[8]
Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper[J]. N Engl J Med, 2023, 389(14):1263-1272.DOI:10.1056/NEJMoa2303452.
[9]
Investigators RC, Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19[J]. N Engl J Med, 2021, 384(16):1491-1502.DOI:10.1056/NEJMoa2100433.
[10]
Kobayashi T, Motoya S, Nakamura S, et al. Discontinuation of infliximab in patients with ulcerative colitis in remission(HAYABUSA):a multicentre,open-label,randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(6):429-437.DOI:10.1016/S2468-1253(21)00062-5.
[11]
Soza A, Heller T, Ghany M, et al. Pilot study of interferon gamma for chronic hepatitis C[J]. J Hepatol, 2005, 43(1):67-71.DOI:10.1016/j.jhep.2005.02.023.
[12]
King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis(INSPIRE):a multicentre,randomised,placebo-controlled trial[J]. Lancet, 2009, 374(9685):222-228.DOI:10.1016/S0140-6736(09)60551-1.
[13]
Roquilly A, Francois B, Huet O, et al. Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients:a phase 2,placebo-controlled randomized clinical trial[J]. Intensive Care Med, 2023, 49(5):530-544.DOI:10.1007/s00134-023-07065-0.
[14]
Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors:American Society of Clinical Oncology clinical practice guideline update[J]. J Clin Oncol, 2015, 33(28):3199-3212.DOI:10.1200/JCO.2015.62.3488.
[15]
Sadik CD, Kim ND, Luster AD. Neutrophils cascading their way to inflammation[J]. Trends Immunol, 2011, 32(10):452-460.DOI:10.1016/j.it.2011.06.008.
[16]
Watson RW, Rotstein OD, Parodo J, et al. The IL-1beta-converting enzyme(caspase-1)inhibits apoptosis of inflammatory neutrophils through activation of IL-1 beta[J]. J Immunol, 1998, 161(2):957-962.DOI:10.4049/jimmunol.161.2.957.
[17]
Christenson K, Bjorkman L, Karlsson A, et al. Regulation of neutrophil apoptosis differs after in vivo transmigration to skin chambers and synovial fluid:a role for inflammasome-dependent interleukin-1beta release[J]. J Innate Immun, 2013, 5(4):377-388.DOI:10.1159/000350378.
[18]
Afford SC, Pongracz J, Stockley RA, et al. The induction by human interleukin-6 of apoptosis in the promonocytic cell line U937 and human neutrophils[J]. J Biol Chem, 1992, 267(30):21612-21616.
[19]
Ottonello L, Frumento G, Arduino N, et al. Differential regulation of spontaneous and immune complex-induced neutrophil apoptosis by proinflammatory cytokines.Role of oxidants,Bax and caspase-3[J]. J Leukoc Biol, 2002, 72(1):125-132.
[20]
Wright HL, Cross AL, Edwards SW, et al. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo[J]. Rheumatology(Oxford), 2014, 53(7):1321-1331.DOI:10.1093/rheumatology/keu035.
[21]
Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer[J]. Nat Rev Immunol, 2018, 18(12):773-789.DOI:10.1038/s41577-018-0066-7.
[22]
Xia Y, Huang P, Qian YY, et al. PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD/E axis in ovarian cancer[J]. J Immunother Cancer, 2024, 12(10):e009032.DOI:10.1136/jitc-2024-009032.
[23]
Ellis TN, Beaman BL. Interferon-gamma activation of polymorphonuclear neutrophil function[J]. Immunology, 2004, 112(1):2-12.DOI:10.1111/j.1365-2567.2004.01849.x.
[24]
Sakamoto E, Hato F, Kato T, et al. Type Ⅰ and type Ⅱ interferons delay human neutrophil apoptosis via activation of STAT3 and up-regulation of cellular inhibitor of apoptosis 2[J]. J Leukoc Biol, 2005, 78(1):301-309.DOI:10.1189/jlb.1104690.
[25]
Wang K, Scheel-Toellner D, Wong SH, et al. Inhibition of neutrophil apoptosis by type 1 IFN depends on cross-talk between phosphoinositol 3-kinase,protein kinase C-delta,and NF-kappa B signaling pathways[J]. J Immunol, 2003, 171(2):1035-1041.DOI:10.4049/jimmunol.171.2.1035.
[26]
Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity[J]. Nat Rev Immunol, 2008, 8(7):533-544.DOI:10.1038/nri2356.
[27]
Manning BD, Toker A. AKT/PKB signaling:navigating the network[J]. Cell, 2017, 169(3):381-405.DOI:10.1016/j.cell.2017.04.001.
[28]
Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin[J]. Science, 1986, 234(4775):470-474.DOI:10.1126/science.3764421.
[29]
Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-gamma[J]. Annu Rev Immunol, 1997, 15(1):749-795.DOI:10.1146/annurev.immunol.15.1.749.
PDF(11270 KB)

Accesses

Citation

Detail

Sections
Recommended

/